Skip to main content
If you continue browsing this website, you agree to our policies:
  • Terms and Conditions
  • Privacy & Cookies Policy
Continue
x
  • Home
  • Calendar
  • About
    About Open Classroom EUPATI Fellows Our Impact FAQ
  • Open Classroom
    Learning Catalogue Patient Expert Training Programme
  • Resources
    Glossary EUPATI Toolbox Patient Engagement Roadmap Accessibility Resources Patient Education Compass
  • EUPATI website
  • More
English ‎(en_wp)‎
Čeština ‎(cs)‎ Deutsch ‎(de_wp)‎ English ‎(en_wp)‎ Español ‎(es_wp)‎ Français ‎(fr_wp)‎ Italiano ‎(it_wp)‎ Nederlands ‎(nl_wp)‎ Português - Portugal ‎(pt)‎ Ελληνικά ‎(el_wp)‎
You are currently using guest access
Log in

    Side Drawer

    EUPATI Open Classroom
    Profile Calendar Home Calendar About Collapse Expand
    About Open Classroom EUPATI Fellows Our Impact FAQ
    Open Classroom Collapse Expand
    Learning Catalogue Patient Expert Training Programme
    Resources Collapse Expand
    Glossary EUPATI Toolbox Patient Engagement Roadmap Accessibility Resources Patient Education Compass
    EUPATI website

    Glossary

    Back

    Investigator's Brochure

    The Investigator's Brochure (IB) is a comprehensive document that summarises all the relevant clinical and non-clinical information about the medicine being studied in humans.

    An IB contains a 'Summary of Data and Guidance for the Investigator' section, the aim of which is 'to provide the investigator with a clear understanding of the possible risks and adverse reactions, and of the specific tests, observations, and precautions that may be needed for a clinical trial.'

    The IB also provides information to help with the clinical management of participants taking part in the clinical trial.

    The sponsor (the organisation running and overseeing the trial) is responsible for keeping the information in the IB up-to-date. The IB is of critical importance. It should be reviewed annually and must be updated when any new and important information becomes available, such as when a medicine has received marketing approval and can be prescribed for use commercially.

    Owing to the importance of the IB for the safety of participants in clinical trials, the International Conference on Harmonisation (ICH) has prepared a detailed guidance document for the authoring of the IB in the European Union, Japan, and the United States.

    » Glossary

    Previous Activity
    Next Activity

    Footer

    You are currently using guest access (Log in)
    Policies
    Get the mobile app
    Powered by Moodle

    About EUPATI

    • About Open Classroom
    • FAQ
    • Contact us

    Start learning

    • Learning Catalogue
    • Patient Expert Training Programme

    Resources

    • EUPATI Toolbox
    • Patient Involvement Roadmap
    • Accessibility Resources

    Terms of Use & Privacy

    • Terms and Conditions
    • Privacy and Cookie Policy

    The EUPATI Open Classroom was initially launched with support from the EUPATI Reload project, funded by EIT Health. EIT Health is supported by EIT, a body of the European Union. 

    For more information about EUPATI, please access our website www.eupati.eu or contact us at openclassroom@eupati.eu

    EIT Health logo and EU logo

    © 2025 EUPATI

    • https://eupati.eu/
    • https://www.linkedin.com/company/15178871/admin/dashboard/
    • https://www.youtube.com/user/PatientsAcademy
    • https://www.instagram.com/eupatients/
    • https://www.facebook.com/eupati.eu/
    Select banner image